Study of CUDC 305 to assess the safety and efficacy in patient with systemic mastocytosis and glioblastoma multiforme.

Trial Profile

Study of CUDC 305 to assess the safety and efficacy in patient with systemic mastocytosis and glioblastoma multiforme.

Planning
Phase of Trial: Phase II

Latest Information Update: 12 May 2015

At a glance

  • Drugs CUDC 305 (Primary)
  • Indications Glioblastoma; Systemic mastocytosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top